Cardiovascular collaboration
Cryptome Pharmaceuticals has signed a memorandum of understanding with the University of Queensland's Institute for Molecular Biosciences (IMB) to collaborate on the identification of potential therapeutics for cardiovascular disease.
The IMB will provide Cryptome with high value compound libraries, which Cryptome will screen for potential activity using its proprietary Cryptomics platform technology. The Cryptomics drug discovery platform is based on finding small protein fragments with previously undiscovered therapeutic activities. These fragments are generated, screened and identified using the Cryptomics systematic high-throughput approach.
Govt announces plan to boost medical science manufacturing
The Australian Government has released the Medical Science Co-investment Plan as part of its...
Early-bird rates and award opportunities at Accreditation Matters
It's just 11 weeks until NATA's accreditation conference, Accreditation Matters. Award...
Aust Academy of Science announces 2024 honorific awards
Researchers from around the country have been recognised by the Australian Academy of Science for...
